Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

Timothy Cloughesy, M.D.
Timothy Cloughesy, M.D.



General Information:



Professor and Director, Department of Neurology, Neurological Services, Neuro-Oncology Program
Physician, Department of Neurology
Member, Brain Research Institute
Member, JCCC Cancer Molecular Imaging Program Area
Member, JCCC Signal Transduction and Therapeutics Program Area

Hospital Affiliation(s):

Ronald Reagan UCLA Medical Center


Neurological Oncology, Memorial Sloan-Kettering Cancer Center, 1991 - 1992
Neurology, UCLA School of Medicine, 1988 - 1991
Neurology, Maricopa Medical Center, 1987 - 1988
Medical Degree:
M.D., Tulane University School of Medicine, 1987

Contact Information:

(310) 825-5321 Neuro-Oncology Program information
(310) 206-6909 Neuro-Oncology Program new patient appointments and referral

Practice Information:

Clinical Interest(s):
Brain Tumor
Neuro Oncology

Scientific Interest(s):

Dr. Timothy Cloughesy's research focuses on clinical trials in brain cancer using targeted molecular therapies with novel clinical trial design. He has developed a brain cancer bioinformatics database which combines clinical outcomes, imaging and molecular analysis to enhance translational research. His goal is to use molecular biology to provide individualized care for brain cancer patients.

Selected Cancer-Related Publications:

Vivanco I, Robins HI, Rohle D, Campos C, Grommes C, Nghiemphu PL, Kubek S, Oldrini B, Chheda MG, Yannuzzi N, Tao H, Zhu S, Iwanami A, Kuga D, Dang J, Pedraza A, Brennan CW, Heguy A, Liau LM, Lieberman F, Yung WK, Gilbert MR, Reardon DA, Drappatz J, Wen PY, Lamborn KR, Chang SM, Prados MD, Fine HA, Horvath S, Wu N, Lassman AB, Deangelis LM, Yong WH, Kuhn JG, Mischel PS, Mehta MP, Cloughesy TF, Mellinghoff IK. Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov. 2012 May;2(5):458-71. Epub 2012 Mar 31

Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009 Oct 1;27(28):4733-40. Epub 2009 Aug 31

Carlson MR, Pope WB, Horvath S, Braunstein JG, Nghiemphu P, Tso CL, Mellinghoff I, Lai A, Liau LM, Mischel PS, Dong J, Nelson SF, Cloughesy TF. Relationship between survival and edema in malignant gliomas: role of vascular endothelial growth factor and neuronal pentraxin 2. Clin Cancer Res. 2007; 13(9): 2592-8.

Schiepers C, Chen W, Dahlbom M, Cloughesy T, Hoh CK, Huang SC. (18)F-fluorothymidine kinetics of malignant brain tumors. Eur J Nucl Med Mol Imaging. 2007; 34(7): 1003-11.

Tso CL, Shintaku P, Chen J, Liu Q, Liu J, Chen Z, Yoshimoto K, Mischel PS, Cloughesy TF, Liau LM, Nelson SF. Primary glioblastomas express mesenchymal stem-like properties. Mol Cancer Res. 2006; 4(9): 607-19.